UK couples are exploiting a loophole in the law to use genetic screening tests to choose their most "desirable" embryos during IVF treatment. The technique, which scores embryos based on predicted IQ, height, and health, is not allowed at UK fertility clinics due to concerns over its scientific validity and ethics.
Under data protection laws, patients are entitled to access their raw genetic data from IVF treatments in the UK, and some have taken advantage of this to send it abroad for analysis by companies such as Herasight. The US-based company offers polygenic screening services for a fee of $50,000 (around ยฃ37,000), which claims to deliver an average IQ gain of six points.
Critics argue that the technique is unproven and raises serious ethical concerns, including the potential for a "stratified society" where wealthier parents can select embryos they deem more desirable. The Human Fertilisation and Embryology Authority (HFEA) has stated that polygenic testing is unlawful for use in the UK, but some fertility clinics are choosing not to block patients' requests for this type of treatment.
One clinic, Avenues in London, has two patients who plan to use Herasight's service without its involvement. The patients hope to reduce the risk of diseases and pick embryos with high predicted IQ. However, experts warn that parents may be disappointed by the results, as "the best" embryo is often a subjective concept.
The debate over polygenic screening in IVF treatment raises questions about the limits of parental choice and the role of technology in family planning. While some see it as a way to give children a better chance at life, others argue that it could lead to a culture of genetic elitism and create unrealistic expectations for parents and their children.
As the use of polygenic screening tests becomes more widespread, regulatory bodies and clinicians must navigate complex questions about the ethics and efficacy of this technology. The HFEA is under pressure to provide clear guidance on its use in the UK, while companies like Herasight must balance their business interests with concerns over scientific validity and public welfare.
Under data protection laws, patients are entitled to access their raw genetic data from IVF treatments in the UK, and some have taken advantage of this to send it abroad for analysis by companies such as Herasight. The US-based company offers polygenic screening services for a fee of $50,000 (around ยฃ37,000), which claims to deliver an average IQ gain of six points.
Critics argue that the technique is unproven and raises serious ethical concerns, including the potential for a "stratified society" where wealthier parents can select embryos they deem more desirable. The Human Fertilisation and Embryology Authority (HFEA) has stated that polygenic testing is unlawful for use in the UK, but some fertility clinics are choosing not to block patients' requests for this type of treatment.
One clinic, Avenues in London, has two patients who plan to use Herasight's service without its involvement. The patients hope to reduce the risk of diseases and pick embryos with high predicted IQ. However, experts warn that parents may be disappointed by the results, as "the best" embryo is often a subjective concept.
The debate over polygenic screening in IVF treatment raises questions about the limits of parental choice and the role of technology in family planning. While some see it as a way to give children a better chance at life, others argue that it could lead to a culture of genetic elitism and create unrealistic expectations for parents and their children.
As the use of polygenic screening tests becomes more widespread, regulatory bodies and clinicians must navigate complex questions about the ethics and efficacy of this technology. The HFEA is under pressure to provide clear guidance on its use in the UK, while companies like Herasight must balance their business interests with concerns over scientific validity and public welfare.